Abstract
In the human body, tumor cell occurrence can be indirectly monitored using the L-selectin concentration in the blood, since selectin ligands are present on the surface of tumor cells, and with tumor progression, a decrease in L-selectin levels can be expected and observed. In this study, we present a selective DNA-based surface-enhanced Raman spectroscopy (SERS) assay for the detection and determination of L-selectin in biological samples. Two calibration curves (linear in the 40–190 ng mL−1 region and exponential in the 40–500 ng mL−1 region) are fitted to the obtained SERS experimental data, i.e., the ratio of I732/I1334 band intensities (LOQ = 46 ng mL−1). Calculated determination coefficients are found to be R2 = 0.997 for the linear region of the calibration curve and R2 = 0.977 for the exponential region. Moreover, we demonstrate very good selectivity of the assay even in the presence of P- and E-selectin in a sample containing L-selectin. With our SERS assay, the L-selectin concentration in biological samples can be estimated directly from the calibration curves.
Graphical abstract
Similar content being viewed by others
References
Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678–98.
Iwata Y, Suzuki K, Nakamura K, Matsuzaki H, Sekine Y, Tsuchiya KJ, Sugihara G, Kawai M, Minabe Y, Takei N, Mori N. Increased levels of serum soluble L-selectin in unmedicated patients with schizophrenia. Schizophr Res. 2007;89:154–60.
Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol. 2007;184(1–2):53–68.
Borsig L. Selectins in cancer immunity. Glycobiology. 2018;28(9):648–55.
Boligan KF, Mesa C, Fernandez LE, Von Gunten S. Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense. Cell Mol Life Sci. 2015;72:1231–48.
Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540–55.
Rosen SD. Ligands for L-selectin: homing, inflammation, and beyond. Annu Rev Immunol. 2004;22:129–56.
Sperandio M, Smith ML, Forlow SB, Olson TS, Xia L, McEver RP, Ley K. P-selectin glycoprotein ligand-1 mediates L-selectin–dependent leukocyte rolling in venules. J Exp Med. 2003;197(10):1355–63.
Majchrzak-Baczmańska DB, Głowacka E, Wilczyński M, Malinowski A. Serum concentrations of soluble (s)L- and (s)P-selectins in women with ovarian cancer. Menopause Rev. 2018;17(1):11–7.
Choudhary D, Hegde P, Voznesensky O, Choudhary S, Kopsiaftis S, Claffey KP, Pilbeam CC, Taylor JA III. Increased expression of L-selectin (CD62L) in high grade urothelial carcinoma: a potential biomarker for metastatic disease. Urol Oncol. 2015;33(9):387.e17-389.e27.
Korniluk A, Kamińska J, Kiszło P, Kemona H, Dymicka-Piekarska V. Lectin adhesion proteins (P-, L- and E-selectins) as biomarkers in colorectal cancer. Biomarkers. 2017;22(7):629–34.
Haznedaroǧlu IC, Benekli M, Ozcebe O, Savaş MC, Güllü IH, Dündar SV, Kirazli Ş. Serum L-selectin and P-selectin levels in lymphomas. Haematologia (Budap). 2000;30(1):27–30.
Clark WM, Lauten JD, Lessov N, Woodward W, Coull BM. Time course of ICAM-1 expression and leukocyte subset infiltration in rat forebrain ischemia. Mol Chem Neuropathol. 1995;26(3):213–30.
Nishijima KI, Ando M, Sano S, Hayashi-Ozawa A, Kinoshita Y, Iijima S. Costimulation of T-cell proliferation by anti-L-selectin antibody is associated with the reduction of a cdk inhibitor p27. Immunology. 2005;116(3):347–53.
Nicholson MW, Barclay AN, Singer MS, Rosen SD, van der Merwe PA. Affinity and kinetic analysis of L-selectin (CD62L) binding to glycosylation-dependent cell-adhesion molecule-1. J Biol Chem. 1998;273(2):763–770.
Cywiński PJ, Olejko L, Löhmannsröben HG. A time-resolved luminescent competitive assay to detect L-selectin using aptamers as recognition elements. Anal Chim Acta. 2015;887:209–15.
Kowalska AA, Nowicka AB, Szymborski T, Piecyk P, Kamińska A. SERS-based sensor for direct L-selectin level determination in plasma samples as alternative method of tumor detection. J Biophotonics. 2021;14(1):1–10.
Le Ru EC, Etchegoin PG. Quantifying SERS enhancements. MRS Bull. 2013;38(8):631–40.
Chen Y, An Q, Teng K, Liu C, Sun F, Li G. Application of SERS in in-vitro biomedical detection. Chem Asian J. 2023;18(4): e202201194.
Perumal J, Wang Y, Attia ABE, Dinish US, Olivo M. Towards a point-of-care SERS sensor for biomedical and agri-food analysis applications: a review of recent advancements. Nanoscale. 2021;13:553–80.
Wan Y, Arif Iftakher MM, Li N, Allen PB, Kim Y, Bachoo R, Iqbal SM, Ellington AD. Nano-textured substrates with immobilized aptamers for cancer cell isolation and cytology. Cancer. 2012;118(8):1145–54.
Nuzzo S, Brancato V, Affinito A, Salvatore M, Cavaliere C, Condorelli G. The role of RNA and DNA aptamers in glioblastoma diagnosis and therapy: a systematic review of the literature. Cancers (Basel). 2020;12(8):1–17.
Affinito A, Quintavalle C, Esposito CL, Roscigno G, Vilardo C, Nuzzo S, Vitiani LR, De Luca G, Pallini R, Kichkailo AS, Lapin IN, de Franciscis V, Condorelli G. The discovery of RNA aptamers that selectively bind glioblastoma stem cells. Mol Ther Nucleic Acids. 2019;18:99–109.
Szymborski T, Stepanenko Y, Niciński K, Piecyk P, Berus SM, Adamczyk-Popławska M, Kamińska A. Ultrasensitive SERS platform made via femtosecond laser micromachining for biomedical applications. J Mat Res Tech. 2021;12:1496–507.
Riese SB, Buscher K, Enders S, Kuehne C, Tauber R, Dernedde J. Structural requirements of mono- and multivalent L-selectin blocking aptamers for enhanced receptor inhibition in vitro and in vivo. Nanomed Nanotechnol Biol Med. 2016;12(4):901–908.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
Measurement for clinical samples was performed in compliance with the relevant laws and institutional guidelines. The protocol of study was approved by the Ethics and Bioethics Committee of Cardinal Stefan Wyszynski University in Warsaw (Poland): Opinion number 13/2019.
Source of biological material
Plasma samples from patients with tumor were collected according to standard best practice and ethics and bioethics guidelines. Informed consent was obtained from all subjects.
Plasma samples from patients with tumor are gathered by the Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, (Lublin, Poland). Human plasma blood samples from 3 healthy patients (healthy tissue samples) were acquired from Regional Blood Center in Warsaw, Poland.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kowalska, A.A., Nowicka, A.B., Szymborski, T. et al. Determination of L-selectin in blood plasma using DNA aptamer–based surface-enhanced Raman spectroscopy assay. Anal Bioanal Chem 416, 1189–1197 (2024). https://doi.org/10.1007/s00216-023-05110-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-023-05110-x